"Financial performance has been solid in the last five years, and the outlook is very strong for the next five. Top-line will grow from $43.5M in 2011 to $110M in 2015, a CAGR of 36%. At the same time, the company has achieved operating leverage with reduced SG&A expenses as a percentage of total revenue. The company will turn profitable in Q1/13 and EPS will grow to $0.18 in 2015. NeoGenomics' growth strategy has been well executed in the past, and we have a high confidence in management's ability to lead the company to the next level of growth in the next five years."